NCT06257641 (MEDIPSO) is a NA clinical trial of High-intensity Mediterranean diet intervention in Psoriasis, sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal.

What drugs are being tested in NCT06257641?

Interventions in NCT06257641: High-intensity Mediterranean diet intervention.

What condition does NCT06257641 study?

NCT06257641 studies Psoriasis, Psoriasis Vulgaris, Hyperlipidemias, Depression, Anxiety, Metabolic Syndrome, Obesity.

Is NCT06257641 still recruiting?

NCT06257641 is currently completed. Last updated 21 March 2025.

Last reviewed 2025-03-21 · How we verify

NCT06257641: MEDIPSO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of the Mediterranean Diet on Patients with Psoriasis

Completed NA Last updated 21 March 2025

What this trial tests

NA trial testing High-intensity Mediterranean diet intervention in Psoriasis in 38 participants. Completed in 10 March 2025.

Timeline

15 February 2024

Primary endpoint
15 January 2025

10 March 2025

Quick facts

Lead sponsor	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	38
Start date	15 February 2024
Primary completion	15 January 2025
Estimated completion	10 March 2025
Sites	1 location across Spain

Drugs / interventions tested

High-intensity Mediterranean diet intervention

Conditions studied

Psoriasis — all drugs for Psoriasis →
Psoriasis Vulgaris — all drugs for Psoriasis Vulgaris →
Hyperlipidemias — all drugs for Hyperlipidemias →
Depression — all drugs for Depression →

Sponsor

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Who can join

Adults 18 to 70, any sex, with Psoriasis or Psoriasis Vulgaris. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to determine the effect of a high-intensity Mediterranean diet intervention over 16 weeks in a group of patients with mild to moderate psoriasis in terms of skin improvement as measured by PASI. In addition, the aim of this study will be to gather the necessary information for a larger and more extended clinical trial in the future. Participants will be provided with dietary education for the implementation of the Mediterranean diet, supported by a monthly follow-up by nutritionists with experience in the field. Researchers will compare the effect of the Mediterranean diet on these patients to a control group provided with standard recommendations for a low-fat diet with no monitoring by nutritionists.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Naturally derived bioactive compounds as precision modulators of immune and inflammatory mechanisms in psoriatic conditions.
Radu A, Tit DM, Endres LM, Radu AF, et al · · 2025 · cited 13× · PMID 39576422 · DOI 10.1007/s10787-024-01602-z
Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial.
Perez-Bootello J, Berna-Rico E, Abbad-Jaime de Aragon C, Goni L, et al · · 2025 · cited 5× · PMID 40991259 · DOI 10.1001/jamadermatol.2025.3410
Impact of the Mediterranean Diet on Patients With Psoriasis: Protocol for a Randomized Controlled Trial.
Perez-Bootello J, Berna-Rico E, Abbad-Jaime de Aragon C, Cova-Martin R, et al · · 2025 · cited 3× · PMID 39879606 · DOI 10.2196/64277

Verify or expand the search:

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal trials

Trials by the same sponsor.

NCT07490964 — Polycystic Ovary Syndrome in Type 1 Diabetes · not yet recruiting
NCT07440186 — Exploratory Clinical Research for the Evaluation of Human GMP (Good Manufacturing Practice) Collagen Implants (Humabiolo · NA · not yet recruiting
NCT07484009 — ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure · NA · recruiting
NCT07034976 — Efficacy of Non-ablative Radiofrequency Combined With Pelvic Floor Muscle Training for Genitourinary Syndrome of Menopau · NA · recruiting
NCT06338072 — Impact of the Menstrual Cycle in Reproductive Aged Women With Type 1 Diabetes Using a Closed Loop System (DIABETEXX/1). · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06257641 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Last refreshed: 21 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06257641.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing